论文部分内容阅读
为了探讨伴inv(16)急性髓细胞白血病(AML)预后的异质性,本研究报道1例伴有显著淋巴结腺体肿大inv(16)AML的诊治经过,并对相关的问题进行了讨论。结果显示:患者男,13岁,确诊M4Eo伴inv(16),并全身显著淋巴结肿大,予以大剂量阿糖胞苷(HDAC)的方案化疗。荧光原位杂交(FISH)技术监测疗效显示患者对HDAC反应不敏感。结论:伴有淋巴结腺体肿大的inv(16)AML对HDAC反应不敏感,预后较不伴淋巴结腺体肿大者差。inv(16)AML预后存在异质性。FISH技术是准确可靠的inv(16)检测手段,可用于监测inv(16)的微小残留病灶。
To investigate the heterogeneity of the prognosis of inv (16) acute myeloid leukemia (AML), one case of diagnosis and treatment of AML with significant lymph node gland enlargement (16) AML was reported in this study and the related issues were discussed . The results showed that the male patient, aged 13, was diagnosed with M4Eo-associated inv (16) and had significant lymphadenopathy throughout the body. He was given high-dose cytarabine (HDAC) regimen. Fluorescence in situ hybridization (FISH) to monitor the efficacy of the treatment showed that the patient is not sensitive to HDAC response. CONCLUSION: Inv (16) AML with lymph node gland enlargement is not sensitive to HDAC, and prognosis is worse than that without lymph node gland enlargement. Inv (16) There is heterogeneity in the prognosis of AML. The FISH technique is an accurate and reliable inv (16) detection tool that can be used to monitor minimal residual lesions of inv (16).